FMP
Avenue Therapeutics, Inc.
ATXI
NASDAQ
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
6.2 USD
-2.5752 (-41.54%)
About
ceo
Dr. Alexandra MacLean M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.avenuetx.com
exchange
NASDAQ
Description
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
CIK
0001644963
ISIN
US05360L3042
CUSIP
05360L205
Address
1140 Avenue of the America
Phone
781 652 4500
Country
US
Employee
3
IPO Date
Jun 27, 2017
Summary
CIK
0001644963
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
05360L205
ISIN
US05360L3042
Country
US
Price
6.2
Beta
-0.26
Volume Avg.
24.06k
Market Cap
4.28M
Shares
-
52-Week
5.78-93.75
DCF
0.17
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.08
P/B
-
Website
https://www.avenuetx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ATXI News
It looks like there's no news available.
